Table 3.
Patient-years of observation and incidence of suspected non-alcoholic fatty liver disease (women with high alanine aminotransferase at baseline excluded) in Italian tamoxifen chemoprevention trial, according to body mass index and treatment group
| Body mass index (kg/m2)
|
Total | |||
|---|---|---|---|---|
| <25 | 25-30 | >30 | ||
| Tamoxifen group | ||||
| Events/woman-year | 7/4670 | 16/3197 | 11/1341 | 34/9208 |
| Rate/100 women/year (%) | 0.15 | 0.50 | 0.82 | 0.37 |
| First and second years: | ||||
| Events/woman-year | 5/2156 | 9/1506 | 7/619 | 21/4281 |
| Rate/100 women/year (%) | 0.23 | 0.60 | 1.13 | 0.49 |
| Third to fifth years: | ||||
| Events/woman-year | 2/2514 | 7/1691 | 4/722 | 13/4927 |
| Rate/100 women/year (%) | 0.08 | 0.41 | 0.55 | 0.26 |
| Placebo group | ||||
| Events/woman-year | 6/4885 | 7/3329 | 5/1405 | 18/9619 |
| Rate/100 women/year (%) | 0.12 | 0.21 | 0.36 | 0.19 |
| First and second years: | ||||
| Events/woman-year | 4/2238 | 2/1537 | 1/665 | 7/4440 |
| Rate/100 women/year (%) | 0.18 | 0.13 | 0.15 | 0.16 |
| Third to fifth years: | ||||
| Events/woman-year | 2/2647 | 5/1792 | 4/740 | 11/5179 |
| Rate/100 women/year (%) | 0.08 | 0.28 | 0.54 | 0.21 |